A Cost-effectiveness Analysis of Genetic Testing in the Evaluation of Families with Hypertrophic Cardiomyopathy - 28/07/11
Doi : 10.1016/j.hlc.2011.05.010
J. Ingles 1, 2, ⁎, J. McGaughran 3, P. Scuffham 4, J. Atherton 5, C. Semsarian 1, 2, 6
1 Molecular Cardiology, Centenary Institute, Australia
2 Central Clinical School, University of Sydney, Australia
3 Genetic Health QLD, Royal Brisbane and Women’s Hospital, Australia
4 Centre for Applied Health Economics, School of Medicine, Griffith University, Australia
5 Department of Cardiology, Royal Brisbane and Women’s Hospital, Australia
6 Department of Cardiology, Royal Prince Alfred Hospital, Australia
Corresponding author.
Il testo completo di questo articolo è disponibile in PDF.
© 2011
Pubblicato da Elsevier Masson SAS.
Vol 20 - N° S2
P. S4 - 2011 Ritorno al numero
Articolo precedente
- The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention
- A. Yong, M. Ho, M. Shah, C. Chawantanpipat, R. O’Connell, A. Keech, L. Kritharides, W. Fearon, M. Ng
- Efficacy of a Pharmacist-Managed Intervention for Improved Blood Pressure Control in Patients with Elevated Cardiovascular Disease Risk: Subgroup Analysis of the HAPPY RCT
- K. Mc Namara, K. Stewart, J. George, S. Jackson, G. Peterson, J. Hughes, M. Bailey, A. Hsueh, L. Bereznicki, P. Gee, R. Lau, D. Bortoletto, J. McDowell
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?